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Abstract
Rat interleukin-5 (IL-5) cDNA was subcloned from peritoneal cells collected 4 h after intraperitoneal injection of Ascaris
suum antigen solution into the immunized rats. Cysteine proteinase-deleted (CPd) rat IL-5 recombinant virus was
constructed by inserting rat IL-5 cDNA into CPd virus having a deletion in the cysteine proteinase gene of the silkworm
Bombyx mori nuclear polyhedrosis virus. On infection with the CPd rat IL-5 recombinant virus, the silkworm B. mori larvae
produced rat IL-5 as a dimeric form in hemolymph. Recombinant rat IL-5 was purified more than 95.5% by anion-exchange
chromatography and hydrophobic chromatography. The purified recombinant rat IL-5 promoted the proliferation of T88-M
cells in a concentration-dependent manner, and its effect was inhibited by an anti-murine IL-5 neutralizing polyclonal
antibody. When bone marrow cells from normal rats were incubated with recombinant rat IL-5 in medium containing
methylcellulose, the colony formation by eosinophilic cells was induced. Furthermore, when rat peritoneal eosinophils were
incubated with recombinant rat IL-5, the spontaneous decrease in the eosinophil viability was inhibited in time- and
concentration-dependent manners. In addition, the recombinant rat IL-5-induced eosinophil survival was inhibited by an
anti-murine IL-5 neutralizing polyclonal antibody. These findings suggest that rat IL-5 acts as B-cell growth factor II
(BCGF-II), eosinophil differentiation factor (EDF), and eosinophil survival-enhancing factor. ß 1999 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Mouse interleukin-5 (IL-5) is reported to act as T-
cell replacing factor (TRF) [1^3], B-cell growth fac-
tor II (BCGF-II) [4], and eosinophil di¡erentiation
factor (EDF) [5,6]. The cloning of cDNA encoding
mouse TRF has revealed that TRF and BCGF-II
belong to a single molecule [7]. In addition, Sander-
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son et al. [5] suggested that BCGF-II is identical to
EDF in mice. Because of the diverse activities and
targets of TRF, this lymphokine is classi¢ed as inter-
leukin and called IL-5 [7]. It is reported that the
migration of eosinophils into the in£ammatory sites,
the survival of mature eosinophils and the immuno-
globulin-induced degranulation of eosinophils are en-
hanced by IL-5 in humans and mice [8^11].
Eosinophils are suggested to play a critical role in
the pathogenesis of allergic diseases including bron-
chial asthma [12^15], allergic rhinitis [16,17], and
atopic dermatitis [18,19]. Bronchial asthma is associ-
ated with in£ammatory reactions involving the accu-
mulation and activation of granulocytes, particularly
eosinophils [20]. It is reported that the number of
eosinophils in asthmatic bronchial mucosa correlates
with disease severity [21,22]. In addition, the number
of eosinophils in the mucosa has been shown to cor-
relate with the level of IL-5 mRNA in humans
[21,23]. It is also reported that IL-5 mRNA levels
correlate with disease severity in atopic asthma [24].
Thus, IL-5 seems to regulate the severity of asthma
through eosinophil activation.
Gene cloning of IL-5 [7,25] and preparation of
recombinant IL-5 [26^29] in humans and mice have
contributed to the understanding of the role of IL-5
in eosinophil functions. As to rat IL-5, Uº berla et al.
[30] cloned its gene, expressed it in T88-M cells and
B13 cells, IL-5-dependent mouse B-cell lines, and
showed BCGF-II activity in the supernatant of the
cells, but they did not isolate and prepare rat IL-5
from the supernatant of the cells. Although rats are
widely used for the analysis of allergic in£ammatory
reactions [31^35], it has not been clari¢ed in rat spe-
cies whether IL-5 functionally acts on eosinophils,
because rat IL-5 was not available.
Therefore, we have intended to prepare recombi-
nant rat IL-5 using a baculovirus expression system,
and examined biological activities of the puri¢ed re-
combinant rat IL-5.
2. Materials and methods
2.1. Preparation of rat eosinophils
Preparation of rat peritoneal eosinophils was car-
ried out according to our previous report [36,37].
The purity of eosinophils in this fraction was more
than 95% as assessed by May^Gru«nwald^Giemsa
staining, and the viability of eosinophils was more
than 98% by Trypan blue exclusion test.
2.2. Cloning of rat IL-5
From 1U108 rat peritoneal cells collected 4 h after
the ¢nal intraperitoneal injection of the antigen so-
lution (day 19), total RNA was prepared by acid
guanidinium thiocyanate^phenol^chloroform extrac-
tion [38]. The ¢rst strand cDNA was synthesized
from 1 Wg of RNA by M-MLV reverse transcriptase
(Gibco-BRL, Gaithersburg, MD, USA) according to
a manufacturer’s procedure. PCR was performed in
50 Wl of 10 mM Tris-HCl bu¡er (pH 8.0) containing
5 Wl of cDNA transcribed from total RNA solution,
50 mM KCl, 1.5 mM MgCl2, 250 WM each of the
dNTPs, 0.2 WM each of the sense and the antisense
primers, and 2.5 U of Taq polymerase (Takara Shu-
zo, Shiga, Japan), using a thermal cycler (GeneAmp
PCR Systems 2400, Perkin Elmer Cetus, Norwalk,
CT, USA). The PCR primers for rat IL-5 were de-
signed from the cDNA sequences of rat IL-5 [30].
The sequences of the primers for rat IL-5 were sense
(5P-GGATCCATGAGGATGCTTCTGTGCTT-3P)
and antisense (5P-GAATTCAGCTCAGTCTCA-
GACTTCC-3P), which amplify a 421-bp fragment
of full length rat IL-5 gene. The PCR cycles to am-
plify rat IL-5 gene consisted of 30 s denaturation at
94‡C, 1 min annealing at 57‡C, and 90 s extension at
72‡C for 30 cycles. The PCR product of rat IL-5
gene was ligated into pGEM-T vector (Promega,
Madison, WI, USA) and transformed into Escheri-
chia coli strain DH5K (Toyobo, Osaka, Japan). The
construct was veri¢ed by DNA sequence analysis us-
ing a DyeDeoxy Terminator Cycle Sequencing Core
kit (Perkin Elmer, Applied Biosystems Division, For-
ster City, CA, USA) and an Applied Biosystems
Model 373A DNA sequencer (Perkin Elmer, Applied
Biosystems Division).
2.3. Construction of recombinant virus
The subcloned rat IL-5 cDNA was cleaved with
BamHI and EcoRI, and the rat IL-5 cDNA was ex-
cised. The cDNA fragment was inserted into BglII^
EcoRI site of pYNG (a transfer plasmid vector), a
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modi¢ed pBM050 vector [39]. The transfer vector
(pYNG rat IL-5) with rat IL-5 gene was puri¢ed
by QIAGEN Plasmid kit (QIAGEN, Hilden, Ger-
many). The puri¢ed plasmid vector was mixed with
puri¢ed cysteine proteinase-deleted (CPd) viral DNA
[40] (transfer vector:viral DNA = 5:2). The mixture
was co-transfected in BoMo15AIIc cells [41] of the
silkworm Bombyx mori larvae using the Lipofectin
Reagent (Gibco-BRL). Recombinant virus was
screened by the endpoint dilution method in 96-
well plates [39], and the polyhedrin negative clone
(CPd rat IL-5) was obtained. The CPd rat IL-5 re-
combinant virus was propagated on BoMo15IIc
cells.
2.4. Viral infection of the silkworm B. mori larvae and
collection of the hemolymph
Culture medium of the BoMo15AIIc cells infected
with the CPd rat IL-5 recombinant virus was used as
inocula for virus infection of larvae of the silkworm
B. mori. The larvae were reared on arti¢cial diet at
27‡C. On the ¢rst day of the 5th-instar, the larvae
were infected by a peroral inoculation method [42].
The infected larvae were reared at 27‡C. Hemolymph
was then collected at 120^144 h postinoculation from
a wound induced by cutting o¡ several abdominal
legs from each larva. A total of four larvae were
used for the collection of hemolymph. Phenylthio-
urea was added to the collected hemolymph to pre-
vent melanization, and the hemolymph sample was
stored at 320‡C.
2.5. Puri¢cation of recombinant rat IL-5
Recombinant rat IL-5 was puri¢ed from the hemo-
lymph of silkworm B. mori larvae infected with CPd
rat IL-5 recombinant virus by anion-exchange chro-
matography and hydrophobic chromatography using
BioCAD/Sprit System (PerSeptive Biosystems, Fra-
mingham, MA, USA). The anion-exchange chroma-
tography and hydrophobic chromatography were
conducted in a POROS PI/M PEEK column and a
POROS PE/M column, respectively. Recombinant
rat IL-5-containing fractions in each puri¢cation
stage were detected by Western blot analysis using
an anti-murine IL-5 neutralizing polyclonal anti-
body. The hemolymph from silkworm B. mori larvae
diluted with 0.1 M Tris-HCl bu¡er (pH 7.0) to 10-
fold was applied to a POROS PI/M PEEK column
equilibrated with 10 mM Tris-HCl bu¡er (pH 7.0),
and eluted with 10 mM Tris-HCl bu¡er (pH 7.0)
containing 1 M NaCl at a £ow rate of 8.0 ml/min.
The £ow-through fractions containing recombinant
rat IL-5, into which ammonium sulfate was added
to give a ¢nal concentration of 1.8 M, were applied
to a POROS PE/M column equilibrated with 20 mM
sodium phosphate bu¡er (pH 7.0) containing 2.1 M
ammonium sulfate. Then, linear gradient elution (2.1
to 0 M ammonium sulfate in 20 mM sodium phos-
phate bu¡er, pH 7.0) was carried out at a £ow rate
of 5.0 ml/min. Recombinant rat IL-5 was detected in
the fractions eluted with 20 mM sodium phosphate
bu¡er containing 0 M ammonium sulfate, and fur-
ther puri¢ed by re-chromatography using the PO-
ROS PE/M column.
2.6. SDS-PAGE and Western blot analysis
Samples incubated for 1 h at room temperature in
loading bu¡er (14% (w/v) sodium dodecylsulfate
(SDS), 5% (v/v) glycerol, 0.05% (w/v) Bromophenol
blue, 20 mM EDTA (pH 8.0), with or without 70
mM dithiothreitol), were applied to a 12.5% (w/v)
SDS-polyacrylamide gel and subjected to electropho-
resis at 20 mA for 4 h. The proteins separated in the
gel were stained using Silver Stain II Kit Wako
(Wako, Osaka, Japan). After the SDS-PAGE, the
proteins in the gels were transferred onto a nitrocel-
lulose membrane and blocked in blocking solution
(Block Ace, Dainoppon, Osaka, Japan). The nitro-
cellulose membrane was incubated overnight at 4‡C
with the primary antibody, goat anti-murine IL-5
neutralizing polyclonal antibody (RpD Systems,
Minneapolis, MN, USA). Thereafter, the membrane
was washed and incubated for 2 h at room temper-
ature with a biotinylated anti-goat IgG (Vector Lab-
oratories, Burlingame, CA, USA). The reaction
products were incubated for 30 min at room temper-
ature with Vectastain ABC reagent (Vector Labora-
tories) and visualized by chemiluminescence detec-
tion systems (ECL Systems, Amersham, Arlington
Heights, IL, USA). The membrane was exposed to
a Kodak X-Omat AR ¢lm (Eastman Kodak, Ro-
chester, NY, USA) for 30 s at room temperature
and photographed.
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2.7. Cell growth assay
T88-M cells [43,44] obtained from RIKEN Gene
Bank (Tsukuba, Japan) were cultured in RPMI-1640
medium, phenol red-free, (Gibco-BRL) supple-
mented with 10% (v/v) heat-inactivated fetal bovine
serum (FBS, Flow Laboratories, North Rydge,
NSW, Australia) containing 10 pM murine IL-5
(RpD Systems). After three washes with medium,
the cells were used for the determination of IL-5
activity. The IL-5 activity was assessed by a modi¢-
cation of the cell growth assay described by Kobaya-
shi et al. [45]. T88-M cells were seeded in each well of
the 96-well plates at a density of 1U104 cells in 0.1
ml of RPMI-1640 medium supplemented with 1% (v/
v) FBS containing various concentrations of re-
combinant rat IL-5 in the presence or absence of
an anti-murine IL-5 neutralizing polyclonal antibody
and incubated for 48 h at 37‡C. Five microliters of
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide, Sigma, St. Louis, MO, USA) solu-
tion (5 mg/ml in PBS) were added to the cells in each
well during the last 4 h of culture. After the removal
of 70 Wl of medium, MTT products were dissolved
with 100 Wl of dimethylsulfoxide, and the absorbance
at 570 nm relative to 630 nm was measured by a
microplate reader (SJeia Auto Reader, Sanko Junya-
ku, Tokyo, Japan).
2.8. Colony formation
Colony formation was performed by a modi¢ca-
tion of the methylcellulose culture method described
by Yamaguchi et al. [46]. Bone marrow cells col-
lected from shinbones and thighbones of normal
rats (Sprague^Dawley strain, male, speci¢c patho-
gen-free, weighing 500^550 g, Charles River, Japan,
Kanagawa, Japan) were seeded in each well of the
6-well plates at a density of 4U104 cells in 4 ml of
1.2% (w/v) methylcellulose (Wako) in KMEM (Gib-
co-BRL) supplemented with 30% (v/v) FBS and 1%
(w/v) bovine serum albumin (BSA, Sigma) in the
presence or absence of 100 pM recombinant rat IL-
5, and incubated for 6 days at 37‡C. The number of
colonies was counted and each colony was suspended
in medium containing 30% (v/v) FBS and 1% (w/v)
BSA. The cells in each colony were identi¢ed after
May^Gru«nwald^Giemsa staining.
2.9. Determination of survival of rat eosinophils
The puri¢ed peritoneal eosinophils were seeded in
each well of the 96-well plates at a density of 1U105
cells in 0.1 ml of RPMI-1640 medium supplemented
with 10% (v/v) FBS containing various concentra-
tions of IL-5 in the presence or absence of an anti-
murine IL-5 neutralizing polyclonal antibody and in-
cubated at 37‡C for the periods indicated. After in-
cubation, the viability of eosinophils was determined
by the ability to exclude Trypan blue dye. The via-
bility of eosinophils was calculated from the follow-
ing equation: viability (%) = [number of cells that
excluded Trypan blue/number of total cells]U100.
2.10. Statistical analysis
The statistical signi¢cance of the results was ana-
lyzed by Dunnett’s test for multiple comparison.
Table 1
Puri¢cation of recombinant rat IL-5
Puri¢cation stage Total proteina
(Wg)
IL-5 contentb





Hemolymph of Bombyx mori larvae infected with
CPd rat IL-5 recombinant virus
86 400 1.2 1040 100
POROS PI/M PEEK column (pooled fractions) 3 590 14.3 513 49.3
POROS PE/M PEEK column (¢nal pooled fractions) 50.7 95.5 48.4 4.7
aTotal protein was determined using the BCA protein assay reagent (Funakoshi, Tokyo, Japan) with bovine serum albumin as a
standard.
bRat IL-5 contents were estimated by densitometric scanning of silver-stained SDS-polyacrylamide gels.
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3. Results
3.1. Production of recombinant rat IL-5
Recombinant rat IL-5 was expressed using a bacu-
lovirus expression system. Recombinant virus for rat
IL-5 (CPd rat IL-5) was constructed from rat IL-5
cDNA prepared from peritoneal cells collected 4 h
after intraperitoneal injection of the antigen solution
into the immunized rats, and used to infect the silk-
worm B. mori larvae. By SDS-PAGE and Western
blot analysis using an anti-murine IL-5 neutralizing
polyclonal antibody, recombinant rat IL-5 was not
detected in hemolymph from wild-type silkworm B.
mori larvae or from silkworm B. mori larvae infected
with the CPd control virus (Fig. 1). In contrast, re-
combinant rat IL-5 was detected in the hemolymph
from silkworm B. mori larvae infected with the CPd
rat IL-5 recombinant virus (Fig. 1). Furthermore,
recombinant rat IL-5 was detected at 30 and 15
kDa by SDS-PAGE and Western blot analysis under
non-reduced and reduced conditions, respectively
(Fig. 1). These ¢ndings suggest that recombinant
rat IL-5 is produced in a dimeric form in hemolymph
from silkworm B. mori larvae infected with the CPd
rat IL-5 recombinant virus.
3.2. Puri¢cation of recombinant rat IL-5
Hemolymph from silkworm B. mori larvae infected
with the CPd rat IL-5 recombinant virus was diluted
with 0.1 M Tris-HCl bu¡er (pH 7.0), and applied to
the POROS PI/M PEEK column. The fraction con-
taining recombinant rat IL-5 was detected by West-
ern blot analysis using an anti-murine IL-5 neutraliz-
ing polyclonal antibody. Most of the recombinant
rat IL-5 was detected in the £ow-through fractions
(data not shown). To the pooled £ow-through frac-
Fig. 1. SDS-PAGE and Western blot analysis of recombinant
rat IL-5 produced in hemolymph of silkworm Bombyx mori lar-
vae. Hemolymph was collected from wild-type silkworm B.
mori larvae (Wild-type) and from silkworm B. mori larvae in-
fected with CPd control virus (CPd) or CPd rat IL-5 recombi-
nant virus (CPd rat IL-5). It was diluted 20-fold with PBS, and
proteins were separated by SDS-PAGE. Recombinant rat IL-5
was analyzed by Western blotting. The analysis was performed
under reduced (+) or non-reduced (3) conditions using dithio-
threitol (DTT). Dimeric and monomeric recombinant rat IL-5
proteins are indicated by closed and open arrow heads, respec-
tively, on the right side. Positions of molecular weight (kDa)
markers are shown on the left side.
Fig. 2. SDS-PAGE and Western blot analysis of the puri¢ed re-
combinant rat IL-5. Puri¢ed recombinant rat IL-5 from hemo-
lymph of silkworm Bombyx mori larvae infected with CPd rat
IL-5 recombinant virus and recombinant murine IL-5 were ana-
lyzed by SDS-PAGE and Western blotting under reduced (+)
or non-reduced (3) conditions using dithiothreitol (DTT). Di-
meric and monomeric IL-5 proteins are indicated by closed and
open arrow heads, respectively, on the right side. Positions of
molecular weight (kDa) markers are shown on the left side.
BBAMCR 14516 30-7-99
K. Ishihara et al. / Biochimica et Biophysica Acta 1451 (1999) 48^5852
tions, ammonium sulfate (pH 7.0) was added to
make a ¢nal concentration of 1.8 M, and the mixture
was applied to the POROS PE/M PEEK column.
Proteins were eluted with a 2.1 to 0 M ammonium
sulfate-linear gradient in 20 mM sodium phosphate
bu¡er (pH 7.0). Recombinant rat IL-5 was detected
by Western blot analysis in fractions eluted at 0 M
ammonium sulfate (data not shown). These fractions
were collected and further puri¢ed by re-chromatog-
raphy using the POROS PE/M PEEK column. The
highly puri¢ed recombinant rat IL-5 was detected by
SDS-PAGE and Western blot analysis at 30 and 15
kDa under non-reduced and reduced conditions, re-
spectively, as recombinant murine IL-5 (Fig. 2). Fi-
nal puri¢cation of recombinant rat IL-5 was more
than 95.5%, and 50.7 Wg of recombinant rat IL-5
was obtained from 1.8 ml (86.4 mg protein) of the
Fig. 3. E¡ects of recombinant rat IL-5 on proliferation of T88-
M cells. (A) T88-M cells (1U104 cells) were incubated for 48 h
at 37‡C in 0.1 ml of RPMI-1640 medium supplemented with
1% (v/v) FBS containing the indicated concentrations of re-
combinant rat IL-5 or 100 pM murine IL-5. (B) T88-M cells
(1U104 cells) were incubated for 48 h at 37‡C in 0.1 ml of
RPMI-1640 medium supplemented with 1% (v/v) FBS contain-
ing the indicated concentrations of anti-murine polyclonal anti-
body (anti-mIL-5 pAb) in the presence of 100 pM recombinant
rat IL-5. The proliferation of T88-M cells was determined by
MTT assay. Values are the means from six samples with
S.E.M. shown by vertical bars. Statistical signi¢cance: (A)
***P6 0.001 vs. vehicle control; (B) ###P6 0.001 vs. 100 pM
rat IL-5 without anti-mIL-5 pAb.
Fig. 4. Microscopic observations of the cells incubated in 1.2%
(w/v) methylcellulose in KMEM supplemented with 30% (v/v)
FBS and 1% (w/v) BSA in the presence of 100 pM recombinant
rat IL-5 for 6 days. (A) Appearance of a typical eosinophilic
colony (original magni¢cation U100). (B) May^Gru«nwald^
Giemsa staining of single cells from an eosinophilic colony.
U200.
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hemolymph from four silkworm B. mori larvae in-
fected with the CPd rat IL-5 recombinant virus (Ta-
ble 1).
3.3. BCGF-II activity of recombinant rat IL-5 in
T88-M cells
Using T88-M cells, B-cell growth factor II (BCGF-
II) activity was determined by MTT assay. Signi¢-
cant increase in the proliferation of T88-M cells was
induced by recombinant rat IL-5 in a concentration-
dependent manner at 0.1^100 pM when determined
48 h after incubation (Fig. 3A). Recombinant rat IL-
5 at 100 pM showed almost the same e¡ect as re-
combinant murine IL-5 at 100 pM (Fig. 3A). The
proliferation of T88-M cells by recombinant rat IL-
5 was inhibited by an anti-murine IL-5 neutralizing
polyclonal antibody in a concentration-dependent
manner (Fig. 3B). These ¢ndings indicate that re-
combinant rat IL-5 possesses BCGF-II activity.
3.4. E¡ects of recombinant rat IL-5 on colony
formation by bone marrow cells
We assessed whether the recombinant rat IL-5
possesses eosinophil di¡erentiation factor (EDF) ac-
tivity. The EDF activity was determined by colony
formation of bone marrow cells (4U104 cells) from
normal rats using the methylcellulose culture meth-
od. After 6 days culture, 17^24 colonies were formed
in the presence of 100 pM recombinant rat IL-5, but
no colony was observed in the absence of IL-5.
Staining of each colony by May^Gru«nwald^Giemsa
revealed that all of these colonies were formed by
eosinophils (Fig. 4B). These ¢ndings indicate that
recombinant rat IL-5 possesses EDF activity.
6
Fig. 5. E¡ects of recombinant rat IL-5 on the viability of rat
eosinophils. (A) Rat peritoneal eosinophils (1U105 cells) were
incubated at 37‡C for the periods indicated in 0.1 ml of RPMI-
1640 medium supplemented with 10% (v/v) FBS containing 100
pM recombinant rat IL-5 (closed circles), 100 pM recombinant
murine IL-5 (open circles), or vehicle (open squares). (B) Rat
peritoneal eosinophils (1U105 cells) were incubated for 96 h at
37‡C in 0.1 ml of RPMI-1640 medium supplemented with 10%
(v/v) FBS containing the indicated concentrations of recombi-
nant rat IL-5 or 100 pM murine IL-5. (C) Rat peritoneal eosin-
ophils (1U105 cells) were incubated for 96 h at 37‡C in 0.1 ml
of RPMI-1640 medium supplemented with 10% (v/v) FBS con-
taining 100 pM recombinant rat IL-5 and the indicated concen-
trations of anti-murine IL-5 neutralizing polyclonal antibody
(anti-mIL-5 pAb). The viability of eosinophils was determined
by the ability to exclude Trypan blue dye. Values are the means
from ¢ve samples. S.E.M. is within each symbol. Statistical sig-
ni¢cance: (A) **P6 0.01, ***P6 0.001 vs. corresponding con-
trol; (B) ###P6 0.001 vs. vehicle control; (C) 222P6 0.001 vs.
100 pM rat IL-5 without anti-mIL-5 pAb.
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3.5. E¡ects of recombinant rat IL-5 on the viability of
rat peritoneal eosinophils
When rat peritoneal eosinophils were incubated at
37‡C, there was a time-dependent decrease of cell
viability (Fig. 5A). Signi¢cant decrease in the viabil-
ity was observed at 48, 72, and 96 h (Fig. 5A). In
contrast, when incubated in the presence of recombi-
nant rat IL-5 at 100 pM, the viability of eosinophils
was maintained till 96 h (Fig. 5A). The viability of
eosinophils incubated in the presence of recombinant
rat IL-5 was signi¢cantly higher than that of control
eosinophils at 24, 48, 72, and 96 h (Fig. 5A). Murine
IL-5 at 100 pM showed the same e¡ect on the via-
bility of rat eosinophils (Fig. 5A). Recombinant rat
IL-5 prolonged the survival of rat eosinophils in a
concentration-dependent manner at 1^100 pM when
examined 96 h after incubation (Fig. 5B). The pro-
longation of the survival of rat eosinophils by re-
combinant rat IL-5 at 100 pM was inhibited by an
anti-murine IL-5 neutralizing polyclonal antibody in
a concentration-dependent manner (Fig. 5C). These
¢ndings indicate that recombinant rat IL-5 possesses
eosinophil survival-enhancing factor activity.
4. Discussion
This is the ¢rst report describing that recombinant
rat IL-5 has been produced in hemolymph of silk-
worm B. mori larvae using a baculovirus expression
system [40]. In addition, puri¢ed recombinant rat IL-
5 has been shown to possess the biological activities
of BCGF-II, EDF, and eosinophil survival-enhanc-
ing factor.
The gene expression vector of the baculovirus, silk-
worm B. mori nuclear polyhedrosis virus (BmNPV),
is suitable for large-scale production of foreign pro-
teins in silkworm B. mori larvae [47]. However, levels
of the foreign gene products tend to decrease in the
later stage of BmNPV infection presumably due, in
part, to a proteinase produced in the larval hemo-
lymph [40]. Ohkawa et al. [48] reported that the deg-
radation of foreign proteins is caused by BmNPV-
derived cysteine proteinase. Suzuki et al. [40] also
reported that CPd baculovirus having a deletion in
the cysteine proteinase gene, produces human growth
hormone more e⁄ciently than wild-type baculovirus.
Therefore, we tried to prepare recombinant rat IL-5
using CPd baculovirus. As detected by Western blot
analysis using an anti-murine IL-5 neutralizing poly-
clonal antibody, recombinant rat IL-5 was e⁄ciently
produced in hemolymph from silkworm B. mori lar-
vae infected with CPd rat IL-5 recombinant virus
(Fig. 1). In the starting materials, viz. 1.8 ml of he-
molymph, the content of recombinant rat IL-5 was
calculated to be 1040 Wg (Table 1). Recombinant rat
IL-5 formed a homodimer as shown by Western blot
analysis after electrophoresis; its molecular weight is
15 and 30 kDa under reduced and non-reduced con-
ditions, respectively (Figs. 1 and 2).
Uº berla et al. [30] suggested that rat IL-5 exhibits
BCGF-II activity in mouse B-cell line T88-M cells
and B13 cells. T88-M cells and B13 cells were prolif-
erated by transfection of rat IL-5 gene or by incuba-
tion with the supernatant of IL-5 gene-transfected
T88-M cells or B13 cells. However, they failed to
show direct e¡ects of recombinant rat IL-5 because
they did not isolate recombinant rat IL-5. We there-
fore examined whether puri¢ed recombinant rat IL-5
directly promotes proliferation of T88-M cells. As
shown in Fig. 3, T88-M cells treated with recombi-
nant rat IL-5 proliferated in a concentration-depend-
ent manner, and this e¡ect was inhibited by an anti-
murine IL-5 neutralizing polyclonal antibody (Fig.
3). These ¢ndings strongly indicate that recombinant
rat IL-5 possesses BCGF-II activity. It is reported
that the e¡ect of IL-5 on B-cells di¡ers between hu-
mans and mice; human IL-5 has no e¡ect as BCGF-
II on human B-cells [49], while mouse IL-5 shows
BCGF-II activity in mouse B-cells [7,28,43] raising
the question of the biological signi¢cance of IL-5
as BCGF-II in mice. In this study, we showed that
recombinant rat IL-5 has BCGF-II activity in a
mouse B-cell line. Because a rat B-cell line is not
available at present, we could not examine BCGF-
II activity of recombinant rat IL-5 in rat B-cells.
Therefore, the experiments cannot give any informa-
tion about the role of rat IL-5 in rat B-cell prolifer-
ation.
In humans and mice, IL-5 commonly acts on eo-
sinophils and their progenitors. For instance, in both
species, IL-5 induces proliferation and di¡erentiation
of bone marrow cells to eosinophils [46], generates
superoxide anions in eosinophils [8,50], and main-
tains eosinophil survival [8,10]. Increase in the num-
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ber of eosinophils is regarded to be a trigger of
pathogenesis of allergic in£ammation, such as asth-
ma and atopic dermatitis in humans and mice [12^
15,18,19]. In rats, although possible participation of
eosinophils in allergic diseases has been studied
[31,32,51], it has not been clari¢ed whether rat IL-5
regulates the function of rat eosinophils. However, it
is reported that the level of rat IL-5 mRNA corre-
lates with increase in the number of eosinophils in
in£ammatory sites [32,51]. Nittoh et al. [52] reported
that immunization and booster injection with Ascaris
suum antigen in rats increase the number of eosino-
philic cells in bone marrow and eosinophils in blood,
and that the number of in¢ltrating eosinophils in
peritoneal cavity after antigen challenge is main-
tained until 48 h. Therefore, to produce recombinant
rat IL-5, we prepared rat IL-5 cDNA from perito-
neal cells in¢ltrating 4 h after injection of A. suum
antigen in the peritoneal cavity of the immunized
rats. Recently, Pierrot et al. [53] reported the expres-
sion of recombinant rat IL-5 using following the two
methods: one is the expression in E. coli as a six
histidine-tagged form and the other is the expression
in Sf9 cells as a GST-fusion form. Their recombinant
proteins have BCGF-II activity on the mouse B-cell
line, B13 cells. However, they did not show another
activities using their recombinant rat IL-5. In this
study, we assessed the biological activities using
more closely natural rat IL-5 than that produced
from GST-fusion protein [53], because our recombi-
nant rat IL-5 has no histidine tag and was expressed
as a biologically active-form homodimer (Figs. 1 and
2). We demonstrated that recombinant rat IL-5 pos-
sesses EDF activity using rat bone marrow cells (Fig.
4), and eosinophil survival-enhancing factor activity
using rat eosinophils in¢ltrating the peritoneal cavity
(Fig. 5), in addition to BCGF-II activity using T88-
M cells (Fig. 3). Our ¢ndings suggest that rat IL-5
regulates the function of rat eosinophils in vivo. The
survival of eosinophils is prolonged by IL-5 not only
in humans and mice, but also in rats.
In conclusion, we succeeded in preparing recombi-
nant rat IL-5 from hemolymph of silkworm B. mori
larvae infected with CPd rat IL-5 recombinant virus.
We found the recombinant rat IL-5 shows BCGF-II
activity, EDF activity, and eosinophil survival-en-
hancing factor activity. The method for preparing
recombinant rat IL-5 described in this paper will be
suitable for large-scale preparation of recombinant
rat IL-5 and useful to study the role of eosinophils
in allergic in£ammation in rats.
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